NASDAQ:DTIL Precision BioSciences (DTIL) Stock Price, News & Analysis $8.37 -0.01 (-0.12%) (As of 11/12/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends About Precision BioSciences Stock (NASDAQ:DTIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Precision BioSciences alerts:Sign Up Key Stats Today's Range$8.20▼$8.4050-Day Range$8.07▼$10.5052-Week Range$7.97▼$19.43Volume200,773 shsAverage Volume77,763 shsMarket Capitalization$64.20 millionP/E Ratio139.52Dividend YieldN/APrice Target$39.50Consensus RatingBuy Company OverviewPrecision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Read More… The gold trades I'm making right now (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Precision BioSciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks83rd Percentile Overall ScoreDTIL MarketRank™: Precision BioSciences scored higher than 83% of companies evaluated by MarketBeat, and ranked 198th out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPrecision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrecision BioSciences has only been the subject of 1 research reports in the past 90 days.Read more about Precision BioSciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($1.23) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is 139.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 130.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is 139.52, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 131.66.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Precision BioSciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.77% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Precision BioSciences has recently increased by 0.05%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.99 Percentage of Shares Shorted5.77% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Precision BioSciences has recently increased by 0.05%, indicating that investor sentiment is decreasing. News and Social Media1.8 / 5News Sentiment0.24 News SentimentPrecision BioSciences has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Precision BioSciences this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,668.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Precision BioSciences is held by insiders.Percentage Held by InstitutionsOnly 37.99% of the stock of Precision BioSciences is held by institutions.Read more about Precision BioSciences' insider trading history. Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address DTIL Stock News HeadlinesPrecision BioSciences, Inc. (NASDAQ:DTIL) CEO Sells $24,668.28 in StockNovember 6, 2024 | insidertrades.comFY2024 Earnings Estimate for DTIL Issued By HC WainwrightNovember 9 at 2:55 AM | americanbankingnews.comThis thing would have won 534 of the 550 trades placed in the last 11 yearsChoosing what your next move will be is one of the most difficult choices investors are faced with today — especially in turbulent markets like these. But what if there was one technique that checked all these boxes? ✅ Allows traders of all stripes to target extra income week after week ✅ Won 534 of 550 trades according to our backtesting on 11-years worth of data ✅ Has maintained a shocking 97.1% through every market condition imaginable ✅ Sets up “Weekly Windfalls” every week so that it’s never trading opposite the broad market direction Well, we’re here to tell you, that strategy isn’t a pipe dream… It’s the same flagship strategy Chris Pulver just released an urgent briefing on! And your friends at Prosperity Pub have secured the video just for you. And with the very next trade dropping THIS WEEK you couldn't have better timing! While we cannot promise future returns or against losses, you have to… November 12, 2024 | ProsperityPub (Ad)Positive Outlook for Precision BioSciences: Buy Rating Affirmed Amid Promising Gene Editing DevelopmentsNovember 6, 2024 | markets.businessinsider.comPrecision BioSciences: Undervalued Gene Editing Innovator with Promising Financial and Clinical ProspectsNovember 6, 2024 | markets.businessinsider.comPrecision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 4, 2024 | businesswire.comPrecision BioSciences (DTIL) Scheduled to Post Quarterly Earnings on MondayNovember 2, 2024 | americanbankingnews.comPrecision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024October 28, 2024 | businesswire.comSee More Headlines DTIL Stock Analysis - Frequently Asked Questions How have DTIL shares performed this year? Precision BioSciences' stock was trading at $10.95 at the start of the year. Since then, DTIL stock has decreased by 23.6% and is now trading at $8.37. View the best growth stocks for 2024 here. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) posted its quarterly earnings data on Thursday, August, 1st. The company reported $3.46 EPS for the quarter, topping the consensus estimate of ($0.77) by $4.23. The firm had revenue of $49.90 million for the quarter, compared to analyst estimates of $8.50 million. Precision BioSciences had a negative trailing twelve-month return on equity of 23.69% and a net margin of 11.48%. When did Precision BioSciences' stock split? Precision BioSciences's stock reverse split on the morning of Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Precision BioSciences IPO? Precision BioSciences (DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO. Who are Precision BioSciences' major shareholders? Precision BioSciences' top institutional investors include Moloney Securities Asset Management LLC (0.44%). Insiders that own company stock include Derek Jantz, J Jefferson Smith, John Alexander Kelly, Dario Scimeca and Alan List. View institutional ownership trends. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), Luminar Technologies (LAZR), CRISPR Therapeutics (CRSP), Palantir Technologies (PLTR), Enovix (ENVX), Nokia Oyj (NOK) and Ginkgo Bioworks (DNA). Company Calendar Last Earnings8/01/2024Today11/12/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/26/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DTIL CUSIPN/A CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$39.50 High Stock Price Target$60.00 Low Stock Price Target$19.00 Potential Upside/Downside+371.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.06 Trailing P/E Ratio139.52 Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,320,000.00 Net Margins11.48% Pretax Margin15.28% Return on Equity-23.69% Return on Assets-6.98% Debt Debt-to-Equity Ratio0.34 Current Ratio9.22 Quick Ratio4.37 Sales & Book Value Annual Sales$48.73 million Price / Sales1.32 Cash FlowN/A Price / Cash FlowN/A Book Value$8.46 per share Price / Book0.99Miscellaneous Outstanding Shares7,670,000Free Float7,364,000Market Cap$64.20 million OptionableNo Data Beta1.71 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:DTIL) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredAmerica is losing powerA massive energy crisis is here … And it’s all because of artificial intelligence. You see, on average, ...Weiss Ratings | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | SponsoredWall Street’s “Secret” Land Grab33-year Wall Street veteran Dylan Jovine says there is one stock that could soar as high as 1,000% or more wit...Behind the Markets | SponsoredBreaking News: Are Trump/Musk Planning an AI Takeover? (Shocking)Now that he is Donald Trump’s right-hand man… You owe it to yourself to see Elon Musk’s big AI prediction f...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.